IDEXX Q2 revenue $944M (+10% organic); EPS $2.67 (+71%); raises 2023 guidance

IDEXX LABORATORIES INC /DE

2023-Q2 EPS reported $5.22 revenue$1,843,825,000

Q2 revenue $944M, +10% reported and organic; CAG Diagnostics recurring revenue +11% reported, +12% organic.
EPS $2.67, +71% reported (+77% comparable); includes $0.04 tax benefit and $0.07 negative FX impact.
Record quarterly premium instrument placements; global installed base grew 11% annually.
Updated 2023 revenue guidance to $3,660M-$3,715M (8.5%-10% growth), EPS guidance to $9.64-$9.90 (20%-23% reported growth).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IDEXX LABORATORIES INC /DE reported second quarter of 2023 results: revenue $944 million, EPS $2.67. Guidance raised.

Period: second quarter of 2023
Revenue: $944 million
EPS: $2.67
Guidance: raised
Result: reported results

Exact text from the filing

The Company reports revenues of $944 million for the second quarter of 2023

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEXX LABORATORIES INC /DE filing history →

Source: SEC EDGAR

accession 0001157523-23-001198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.